Group items tagged

As many more premature infants survive, the numbers of these infants with health problems increases. The rate of cerebral palsy (CP) in extremely premature infants is approximately 20%. Magnesium sulfate, the most commonly used drug in the US to stop premature labor, may prevent CP. This trial tests whether magnesium sulfate given to a woman in labor with a premature fetus (24 to 31 weeks out of 40) will reduce the rate of death or moderate to severe CP in the children at 2 years. The children receive ultrasounds of their brains as infants and attend three follow-up visits over two years to assess their health and development.

NIH, and Eunice Kennedy Shriver National Institute of Child Health and Human Development - Review and trial to determine whether magnesium sulfate administered to women at risk of preterm delivery may reduce the risk of cerebral palsy in their children

Article from The New England Journal of Medicne - offering information on a Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy

National Library of Medicine National Institutes of Health PubMed Abstract: Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks gestation: a systematic reiew and metaanalysis

Magnesium Sulfate Study for the Prevention of Cerebral Palsy

Archive from Cerebral Palsy Internation Research Foundation. Results of study conducted to examine the effect of magnesium sulfate on the rate of stillbirth or infant death and rate of moderate or severe cerebral palsy at or after the after of 2 years

To evaluate the safety and efficacy of magnesium sulfate for preterm suspected abruption

Magnesium is neuroprotective in neonatal animal models of acquired hypoxic-ischemic and/or inflammatory cerebral lesions. It is associated with a significant reduction of perinatal death and cerebral palsy in some observational studies.The objective of the study is to assess if prenatal magnesium sulfate given to women at risk of preterm birth before 33 week's gestation is neuroprotective

Multicenter, randomized, controlled trial to compare the anti-seizure effect of parenteral MgSO4 versus oral labetalol in hypertensive pregnant women who are eligible for MgSO4 therapy. The primary outcome measure is eclampsia, and the secondary outcome measures include blood pressure control, and relevant antenatal, intrapartum, and postnatal maternal and fetal/neonatal parameters including adverse effects and complications.

Study sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development NICHD will evaluate the effects of giving magnesium to premature infants.